ESMO 2024: Clinical Prognostic Factors Within the High-Volume Subgroup of Metastatic Hormone Sensitive Prostate Cancer in ENZAMET (ANZUP 1304) ESMO 2024: HARMONY: A Phase II Study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback